Hospital Israelita Albert Einstein

South Korean AI company Lunit has tied up with its investor, Guardant Health, for AI integration. Under the partnership, Lunit will integrate its PD-L1 scoring algorithm into Guardant's cancer biomarker detection workflow in the Guardant360 TissueNextTM PD-L1 test for non-small cell lung cancer (NSCLC). Lunit SCOPE PD-L1, a CE-marked AI solution, detects and analyses PD-L1, a type of cancer biomarker. WHY IT MATTERS The Lunit SCOPE PD-L1 does AI-based quantification of tissue samples using a scoring system. Integrating it with the Guardant test will enhance biomarker assessment for NSCLC patients, the company claimed in a press statement. The AI has helped lift the test's detection of PD-L1 by over 20% compared to manual pathologist interpretation. THE LARGER TREND In 2021, Guardant Health backed Lunit's Series C Tranche B funding round with a $26 million investment. The company previously said that it expects its investment in the company to be used in developing new precision oncology products that improve cancer care. On Thursday, Guardant Health formally introduced Guardant Galaxy, its suite of analytical technologies developed internally and through outside partnerships. The Guardant360 TissueNext PD-L1 test integrated with Lunit SCOPE PD-L1 is the first application in this line. In other related news, Lunit opened the new year with a three-year deal to supply its AI chest x-ray image analysis software, Lunit INSIGHT CXR, to Hospital Israelita Albert Einstein, one of the biggest hospitals in Brazil. ON THE RECORD "The digital pathology solution from Lunit has already demonstrated the power of AI to help improve [the] detection of PD-L1 in certain cases of NSCLC. We believe it has the potential to contribute much more broadly to advances in identifying cancer biomarkers and informing treatment decisions," Guardant Health co-CEO Helmy Eltoukhy said about Lunit's AI solution. "The development of the AI-supported scoring algorithm for the Guardant360 TissueNext PD-L1 test is a great example of using advanced medical image analytics to enhance precision diagnostics in lung cancer and help doctors find the right treatment for the right patients," Lunit CEO Brandon Suh also commented.

Dozee scores 510(k) for AI contactless sensor for RPM Indian medical device company Dozee has received the United States Food and Drug Administration's 510(k) clearance for its proprietary contactless sensor for remote patient monitoring. The Dozee sensor sheet, which is placed under a hospital bed mattress, captures micro-vibrations from patients using Ballistocardiography. These vibrations are then converted into vital signs data, including heart and respiration rates, which are presented via a cloud-based remote monitoring dashboard to healthcare teams. According to Dozee, this latest regulatory win allows it to realise its mission of bridging the gap in healthcare staffing shortage by promoting the adoption of automated patient monitoring systems across secondary and tertiary public hospitals in India and beyond. SURGLASSES gets 510(k) for AR spinal navigation system Taiwan Main Orthopaedic Biotechnology Co., also known as SURGLASSES, has also obtained a US FDA 510(k) clearance for its AR-based spine navigation system, Caduceus S. Intended for use in complex spine surgeries, the AR system allows surgeons to superimpose 3D spinal anatomy on a patient. The system is also equipped with multiple trackers and displays preoperative planned trajectories via a 3D AR head-mounted display, which enables projections from the navigation system into the HMD and provides a full field view of the patient. This latest 510(k) clearance, which followed Taiwan FDA's approval in August, allows SURGLASSES to launch its spinal navigation system in the US in the first quarter of 2023. Lunit secures AI contracts in Hong Kong, Mongolia, Brazil South Korean medical AI company Lunit signed several contracts this week to deliver its Lunit INSIGHT AI imaging solutions in multiple markets. Its chest x-ray solution INSIGHT CXR will be deployed at Albert Einstein Israelita Hospital in Brazil, one of the largest hospitals in Latin America. Lunit INSIGHT MMG, its AI mammography solution, will also be dispatched to Hong Kong Women's Imaging Hospital in Hong Kong and to two more sites in Mongolia, the National Cancer Center of Mongolia and the Breast Clinic of Ulaanbaatar. AI brain imaging solution Neurophet Aqua enters Japan Another South Korean medical AI player, Neurophet, has entered into a partnership to commercialise its AI-powered brain imaging solution in Japan. The company inked an exclusive distribution deal with Clairvo Technologies, a medical device importer under the Marubeni Group, to market its flagship product Neurophet Aqua. The product is a degenerative neurological disease diagnosis support software that detects brain atrophy and degeneration of the white matter as observed in neurodegenerative diseases like Alzheimer's disease and vascular dementia. It can generate an analysis report within five minutes, Neurophet claims. Ubitus carries Smart Surgery's VR surgery simulation app Taipei-based metaverse solution provider Ubitus is rolling out a VR-driven surgery simulation application by Smart Surgery Technology. Aiming to make the surgical practice accessible to medical students and doctors, the Sim Surgery app provides a visual experience of operating on 3D organ models using personal VR. It also uses AI to help practitioners make accurate judgments in conducting surgery. Running on Ubitus, Smart Surgery can stream high-quality 3D anatomical models to an all-in-one VR headset without the need for a high computing power device onsite. FWD Group offers mental health access from ThoughtFull Singaporean startup ThoughtFull has tied up with FWD Group to provide insurance customers with access to digital mental health solutions. This partnership will allow FWD's insurance clients to access a wide range of services and tools on ThoughtFull's AI-powered mobile platform ThoughtFullChat, including video therapy, one-on-one therapy sessions, mental health coaching via text and audio messaging, science-backed content and emotional health trackers. These services are part of FWD's Mind Strength protection product, which provides extensive medical coverage from initial diagnosis to ongoing treatment. Access to ThoughtFullChat is now live for FWD clients in Hong Kong and Thailand with other selected FWD markets to follow in the future. XtalPi, Singapore's EDDC collab for AI drug research on NSCLC treatment China and US-based AI drug R&D company XtalPi is partnering with Singapore's national platform for drug discovery and development, Experimental Drug Development Centre (EDDC). XtalPi will be applying its AI technology, automation platform, and expert knowledge to discover novel treatment candidates against a non-small cell lung cancer (NSCLC) target chosen by EDDC. NSCLC accounts for over 80% of all lung cancer cases worldwide. Despite increasing interest and investment in drug research, there are still major unmet needs for effective targeted therapy options for NSCLC patients to achieve better outcomes, XtalPi noted. SmartFuture unveils integrated first responder platform Singapore-based health tech company SmartFuture has launched a new integrated rapid response solution. According to a press statement, the First Responder Platform enables real-time monitoring of health vitals, doctor consultation, and timely action during emergency situations. It consists of a kit for connected medical devices, a tablet-based first responder application, and a web portal for partner emergency assistance providers. SmartFuture said its latest offering is ideal for offshore locations, such as oil and gas, shipping, airlines and mining; emergency response services like fire fighting, ambulance, and disaster response; and educational institutions for their field trips.

College of Medicine to Partner with Columbia University Irving Medical Center, the Icahn School of Medicine at Mount Sinai, and Renaissance School of Medicine at Stony Brook University BRONX, N.Y., Nov. 16, 2022 /PRNewswire/ -- The National Institutes of Health has awarded Albert Einstein College of Medicine a five-year, $6.6 million grant to lead a New York-based consortium of medical schools to train young scientists in kidney, urology, and hematology research. The grant establishes the New York Consortium for Interdisciplinary Training in Kidney, Urological, and Hematological Research, or NYC Train KUHR (pronounced "cure"), bringing together experts in research and education from Einstein, Columbia University Irving Medical Center, the Icahn School of Medicine at Mount Sinai, and Renaissance School of Medicine at Stony Brook University. "With NYC Train KUHR, more than 100 scientists skilled in kidney, urologic, and hematologic (KUH) disease research will work together to mentor pre- and post-doctoral fellows in interdisciplinary research involving these specialties," said Michal Melamed, M.D., M.S., the grant's lead principal investigator and professor of medicine, of pediatrics, and of epidemiology & population health at Einstein and a nephrologist at Montefiore Health System. "These specialties are deeply intertwined and it's critical to train a new generation of investigators who can comfortably navigate these fields and lead research to improve the care and quality of life for people with KUH diseases. "Many of the diseases the trainees will focus on—such as sickle cell disease and kidney disease—disproportionately affect Black and Hispanic people, and other marginalized groups," continued Dr. Melamed. "We are particularly hopeful that advancing this interdisciplinary training will benefit our Bronx community." NYC Train KUHR is the only NIH-funded consortium focused on KUH disease research and training in the Northeast and one of only seven nationally. Trainees selected to participate in the program will have at least two mentors, who will help guide and inform their research. "Many of the diseases of these three body systems result in complications that impact how the others function, so it's imperative to reach across disciplines to effectively treat disease," said co-principal investigator Jonathan Barasch, M.D., professor of medicine, of pathology, and of cell biology at Columbia University Irving Medical Center. "While this program is focused on training early career physicians and scientists, we expect that the participating faculty members will also benefit from increased collaborations across institutions." The new grant builds on decades of established training programs at some of the participating institutions. "Individually, our institutions have impressive track records in basic science, translational, and clinical research achievements within these conditions. Together our strengths are magnified, and we can share our collective expertise with new trainees who will continue to make advances in the field," said Kirk Campbell, M.D., professor of medicine and co-principal investigator at Icahn School of Medicine at Mount Sinai. NYC Train KUHR will recruit up to 10 trainees each year who will have opportunities to work under mentors from various institutions, access data and scientific models from past and current studies, and attend regular networking and professional development presentations. The grant also will enable the creation of an undergraduate summer program for students from groups historically underrepresented in medicine who are interested in kidney, urology, or hematology research. "A key priority is enriching the diversity of physicians and researchers in our fields," said co-principal investigator Sandeep Mallipattu, M.D., chief of the division of nephrology and hypertension at Renaissance School of Medicine at Stony Brook University. Other co-principal investigators and project leaders on the grant include Frederick Kaskel, M.D., Ph.D., and Kelvin Davies, Ph.D., at Einstein; Wadie Bahou, M.D., at Renaissance School of Medicine at Stony Brook University; Nancy Green, M.D., at Columbia University Irving Medical Center; and Margaret Baron, M.D., Ph.D., at Icahn School of Medicine at Mount Sinai. The grant, titled "New York Consortium for Interdisciplinary Training in Kidney, Urological and Hematological Research (NYC Train KUHR)," was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the NIH. (1U2CDK129502 and 1TL1DK136048) About Albert Einstein College of Medicine Albert Einstein College of Medicine is one of the nation's premier centers for research, medical education and clinical investigation. During the 2022-23 academic year, Einstein is home to 740 M.D. students, 194 Ph.D. students, 118 students in the combined M.D./Ph.D. program, and approximately 225 postdoctoral research fellows. The College of Medicine has more than 1,900 full-time faculty members located on the main campus and at its clinical affiliates. In 2022, Einstein received more than $202 million in awards from the National Institutes of Health. This includes the funding of major research centers at Einstein in cancer, aging, intellectual development disorders, diabetes, clinical and translational research, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Its partnership with Montefiore, the University Hospital and academic medical center for Einstein, advances clinical and translational research to accelerate the pace at which new discoveries become the treatments and therapies that benefit patients. For more information, please visit einsteinmed.edu, follow us on Twitter, Facebook, Instagram, LinkedIn, and view us on YouTube. SOURCE Albert Einstein College of Medicine